We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+31.09%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$9.98B
AUM Growth
+$1.87B
Cap. Flow
+$293M
Cap. Flow %
2.94%
Top 10 Hldgs %
50.46%
Holding
103
New
29
Increased
20
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$321M
2
IRTC icon
iRhythm Holdings
IRTC
+$209M
3
APLS
Apellis Pharmaceuticals
APLS
+$180M
4
RGEN icon
Repligen
RGEN
+$167M
5
COGT icon
Cogent Biosciences
COGT
+$116M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$496M
2
AKRO
Akero Therapeutics
AKRO
+$260M
3
MRUS
Merus
MRUS
+$191M
4
NTRA icon
Natera
NTRA
+$104M
5
SYK icon
Stryker
SYK
+$89.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAPR icon
76
Capricor Therapeutics
CAPR
$237M
$7.21M 0.07%
+250,000
New +$3.26M
GPCR icon
77
Structure Therapeutics
GPCR
$3.78B
$6.96M 0.07%
+100,000
New +$4.08M
IVA
78
Inventiva
IVA
$1.13B
$6.04M 0.06%
+1,298,701
New +$6.03M
MIST icon
79
Milestone Pharmaceuticals
MIST
$152M
$5.06M 0.05%
2,506,102
– –
XGN icon
80
Exagen
XGN
$166M
$4.81M 0.05%
790,462
-906,404
-53% -$8.25M
TENX icon
81
Tenax Therapeutics
TENX
$503M
$4.61M 0.05%
378,346
– –
CBIO
82
Crescent Biopharma
CBIO
$626M
$4.42M 0.04%
+372,856
New +$4.75M
DFTX
83
Definium Therapeutics
DFTX
$6.12B
$4.02M 0.04%
+300,000
New +$3.71M
FDMT icon
84
4D Molecular Therapeutics
FDMT
$562M
$3.57M 0.04%
+475,737
New +$4.83M
CRVS icon
85
Corvus Pharmaceuticals
CRVS
$1.17B
$3.45M 0.03%
447,607
-2,231,872
-83% -$17.6M
OMDA
86
Omada Health Inc
OMDA
$1.41B
$3.16M 0.03%
200,000
– –
MDLN
87
Medline Inc
MDLN
$30.9B
$2.94M 0.03%
+70,000
New +$2.96M
IRON icon
88
Disc Medicine
IRON
$2.97B
$2.38M 0.02%
+30,000
New +$2.53M
IMA
89
ImageneBio Inc
IMA
$64.6M
$2.31M 0.02%
334,445
– –
ERAS icon
90
Erasca
ERAS
$6.39B
$546K 0.01%
+146,651
New +$412K
RCKTW icon
91
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$8.51K ﹤0.01%
350,000
– –
ABVX
92
Abivax
ABVX
$11.4B
– –
-350,000
Closed -$29.7M
AKRO
93
DELISTED
Akero Therapeutics
AKRO
– –
-5,477,561
Closed -$260M
ALEC icon
94
Alector
ALEC
$199M
– –
-6,990,806
Closed -$20.7M
CTMX icon
95
CytomX Therapeutics
CTMX
$754M
– –
-3,461,500
Closed -$11M
DGX icon
96
Quest Diagnostics
DGX
$26.3B
– –
-250,000
Closed -$47.6M
DYN icon
97
Dyne Therapeutics
DYN
$4.9B
– –
-2,890,567
Closed -$36.6M
GEHC icon
98
GE HealthCare
GEHC
$32.4B
– –
-393,500
Closed -$29.6M
MRUS
99
DELISTED
Merus
MRUS
– –
-2,025,277
Closed -$191M
PEPG icon
100
PepGen
PEPG
$197M
– –
-1,500,000
Closed -$6.93M
1 2 3
4
5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2025 Portfolio in Review

As of Q4 2025, RTW Investments held 103 positions worth $9.98B, up 23% from $8.12B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments's Q4 2025 filing shows 29 new, 20 increased, 12 reduced and 12 closed positions. Its largest new stake was iRhythm Holdings: 1,181,990 shares worth $210M. The largest sale was Avidity Biosciences, an estimated $496M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q4 2025 buy was iRhythm Holdings: 1,181,990 shares worth $210M.
  • RTW Investments added most to Insmed in Q4 2025, an estimated $321M increase.
  • RTW Investments's biggest Q4 2025 reduction was Natera, cutting an estimated $104M.
  • RTW Investments fully exited Avidity Biosciences in Q4 2025, selling an estimated $496M.
  • RTW Investments's ten largest holdings make up 50% of its $9.98B portfolio in Q4 2025.
  • RTW Investments opened 29 new positions and closed 12 in Q4 2025.
  • RTW Investments's portfolio value rose 23% quarter-over-quarter to $9.98B.

Based on RTW Investments's 13F filing for Q4 2025, filed 17 Feb 2026.